Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2202-2205

  Zhou, Xiao Jian ^a   Gruber, William ^b   Demmler, Gail ^c   Jacobs, Richard ^d   Reuman, Peter ^e   Adler, Stuart ^f   Shelton, Mark ^g   Pass, Robert ^a   Britt, Bill ^a   Trang, John M ^a   Whitley, Richard J ^a   Sommadossi, Jean Pierre ^a,h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c BAYLOR UNIVERSITY   (United States)

^d UNIVERSITY OF ARKANSAS   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Department of Hematology Oncology   (United States)

^h Volker Hall G019 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL INFECTION; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; NEWBORN INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 9544248770     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2202     Document Type: Article

References (24)

1. Beal, S. L., and L. B. Sheiner. 1992. NONMEM user's guide. University of California at San Francisco, San Francisco.
2. Buhles, W. C., Jr., B. J. Mastre, A. J. Tinker, V. Strand, S. H. Koretz, and the Syntex Collaborative Ganciclovir Treatment Study Group. 1988. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev. Infect. Dis. 10:S495-S506.
3. Deitrich, D. T., A. Chachoua, F. Lafleur, and C. Worrell. 1988. Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. Rev. Infect. Dis. 10:S532-S537.
4. Faulds, D., and R. C. Heel. 1990. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 30:597-638.
5. Field, A. K., M. E. Davies, C. DeWitt, M. C. Perry, R. Liou, J. Germershausen, J. D. Karkas, W. J. Ashton, D. B. R. Johson, and R. L. Tolman. 1983. 9-([2-Hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80:4139-4143.
6. Fletcher, C., R. Sawchuk, B. Chinnock, P. DeMiranda, and H. H. Balfour. 1986. Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40:281-286.
7. Fong, J., S. Johnston, T. Valentino, and D. Notterman. 1995. Length/serum creatinine ratio does not predict measured creatinine clearance in critically ill children. Clin. Pharmacol. Ther. 58:192-197.
8. Harbison, M. A., P. C. DeGirolami, R. L. Jenkins, and S. M. Hammer. 1988. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 46:82-86.
9. Keay, S., E. Petersen, T. Icenogle, B. J. Zeluff, T. Samo, D. Busch, C. L. Newman, W. C. Buhles, and T. C. Merigan. 1988. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev. Infect. Dis. 10:S563-S572.
10. Kwong, M. B. L., T. K. Tong, J. J. Mickell, and C. M. Chan. 1985. Lack of evidence that formular-derived creatinine clearance approximates glomerular filtration rate in pediatric intensive care population. Clin. Nephrol. 24: 285-288.
11. Laskin, D. L., D. M. Cederbert, J. Mills, L. J. Eron, D. Mildvan, S. A. Spector, and the Ganciclovir Study Group. 1987. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am. J. Med. 83:201-207.
12. Mar, E. C., Y. C. Cheng, and E. S. Huang. 1983. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24:518-521.
13. Martin, J. C., C. A. Dvorack, D. E. Smee, T. R. Matthews, and J. P. H. Verheyden. 1983. 9-[1,3-Dihydroxy-2-propoxy) methyl]guanine: a new potent and selective antiherpes agent. J. Med. Chem. 26:759-761.
14. Paul, S., and S. Dummer. 1992. Topics in clinical pharmacology: ganciclovir. Am. J. Med. Sci. 304:272-277.
15. Schwartz, G. J., L. P. Brion, and A. Spitzer. 1987. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. N. Am. 34:571-590.
16. Snydman, D. R. 1988. Ganciclovir therapy for cytomegalovirus disease associated with renal transplants. Rev. Infect. Dis. 10:S554-S562.
17. Sommadossi, J. P., and R. Bevan. 1987. High performance liquid chromatographic method for the determination of 9-(1,3-dihydroxy-2-propoxymethyl) guanine in human plasma. J. Chromatogr. 414:429-433.
18. Sommadossi, J. P., R. Bevan, T. Ling, F. Lee, B. Mastre, M. D. Chaplin, C. Nerenberg, S. Koretz, and C. Buhles, Jr. 1988. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev. Infect. Dis. 10(Suppl. 3):S507-S514.
19. Swan, S. K., M. Y. Munar, M. A. Wigger, and W. M. Bennett. 1991. Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am. J. Kidney Dis. 17:69-72.
20. Tocci, M. J., T. Livelli, H. C. Perry, C. S. Crumpacker, and A. K. Field. 1984. Effects of the nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication. Antimicrob. Agents Chemother. 25:247-252.
21. Trang, J. M., L. Kidd, W. Gruber, G. Storch, G. Demmler, R. Jacobs, W. Danker, S. Starr, R. Pass, S. Stagno, C. Alford, S. J. Soong, R. J. Whitley, J. P. Sommadossi, and the NIAID Collaborative Antiviral Study Group. 1993. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin. Pharmacol. Ther. 53:15-21.
22. Weller, S., S. H. T. Liao, D. M. Cederberg, P. deMiranda, and M. R. Blum. 1987. The pharmacokinetics of ganciclovir in patients with cytomegalovirus (CMV) infections. J. Pharm. Sci. 76:S120.
23. Yuen, G. J., G. L. Drusano, C. Fletcher, E. Capparelli, J. D. Connor, J. P. Lalezari, L. Drew, S. Follansbee, D. Busch, M. Jacobson, S. A. Spector, K. Squires, and W. Buhles. 1995. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob. Agents Chemother. 39:2350-2352.
24. Zacchello, G., M. Bondio, O. S. Saia, G. Largaiolli, R. Vedaldi, and F. F. Rubaltelli. 1982. Simple estimate of creatinine clearance from plasma creatinine in neonates. Arch. Dis. Child. 57:297-300.